CD274 and breast carcinoma: Accordingly, several monoclonal antibodies (mAbs) targeting PD-1 (pembrolizumab and nivolumab) and PD-L1 (atezolimumab) interaction have received FDA approval for the treatment of various lethal cancers including metastatic melanoma, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, and breast cancer, among others (218).